NDC 51662-1420

NALBUPHINE HCI

Nalbuphine Hci

NALBUPHINE HCI is a Intramuscular; Intravenous; Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Hf Acquisition Co Llc, Dba Healthfirst. The primary component is Nalbuphine Hydrochloride.

Product ID51662-1420_96139914-0709-7b58-e053-2995a90a7308
NDC51662-1420
Product TypeHuman Prescription Drug
Proprietary NameNALBUPHINE HCI
Generic NameNalbuphine Hci
Dosage FormInjection, Solution
Route of AdministrationINTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2019-10-29
Marketing CategoryANDA / ANDA
Application NumberANDA070915
Labeler NameHF Acquisition Co LLC, DBA HealthFirst
Substance NameNALBUPHINE HYDROCHLORIDE
Active Ingredient Strength10 mg/mL
Pharm ClassesCompetitive Opioid Antagonists [MoA],Opioid Agonist/Antagonist [EPC],Partial Opioid Agonists [MoA]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 51662-1420-1

1 VIAL, MULTI-DOSE in 1 CARTON (51662-1420-1) > 10 mL in 1 VIAL, MULTI-DOSE
Marketing Start Date2019-10-29
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 51662-1420-1 [51662142001]

NALBUPHINE HCI INJECTION, SOLUTION
Marketing CategoryANDA
Application NumberANDA070915
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-10-29

Drug Details

Active Ingredients

IngredientStrength
NALBUPHINE HYDROCHLORIDE10 mg/mL

Pharmacological Class

  • Competitive Opioid Antagonists [MoA]
  • Opioid Agonist/Antagonist [EPC]
  • Partial Opioid Agonists [MoA]

NDC Crossover Matching brand name "NALBUPHINE HCI" or generic name "Nalbuphine Hci"

NDCBrand NameGeneric Name
51662-1418NALBUPHINE HCINALBUPHINE HCI
51662-1420NALBUPHINE HCINALBUPHINE HCI

© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.